Table 1.
Participant demographics
| Full sample | IBD | Healthy control | Significance test | |
| Age | 43.65 years (SD=15.52) | 43.80 years (SD=15.07) | 43.38 years (SD=17.39) | p=0.95 |
| Gender | 60.9% women | 60% women | 62.5% women | p=1.0 |
| Race | 87% white | 93.3% white | 75% white | p=0.53 |
| IBD type and location | – | 9 Crohn’s disease Location: 4 ileal only 3 ileocolonic 2 colonic only Behavior: 3 inflammatory 4 stricturing 2 penetrating Perianal Involvement: 4 yes 5 no 6 ulcerative colitis Extent: 5 left-sided disease 1 proctitis |
– | – |
| Years since IBD diagnosis | – | M=31.53, SD=13.88 | – | – |
| IBD medications | – | 3 adalimumab 1 azathioprine 3 infliximab 3 mesalamine 1 methotrexate 1 sulfasalazine 2 ustekinumab 2 vedolizumab 2 prednisone (<10 mg) |
– | – |
| Sleep and/or psychiatric medications* | – | 3 antidepressants (citalopram, fluoxetine, bupropion) 1 anticonvulsant 1 atypical antipsychotic |
– | – |
| Sleep quality (PSQI) | M=7.13, SD=4.37 | M=8.93, SD=3.71 | M=3.75, SD=3.54 | p=0.004 |
| Insomnia severity (ISI) | M=8.96, SD=7.70 | M=12.13, SD=7.31 | M=3.00, SD=4.14 | p=0.004 |
| Anxiety (GAD-7) | M=5.05, SD=6.22 | M=7.79, SD=6.34 | M=0.25, SD=0.46 | p=0.003 |
| Depression (PHQ-9) | M=4.64, SD=5.62 | M=7.14, SD=5.67 | M=0.25, SD=0.71 | p=0.003 |
| Pain catastrophizing (PCS) | M=9.0, SD=9.34 | M=11.64, SD=10.34 | M=4.38, SD=4.98 | p=0.08 |
Bolded values are significant at p<0.05.
*Sleep and psychiatric medications not reported by healthy controls.
GAD-7, Generalized Anxiety Disorder-7; IBD, inflammatory bowel disease; ISI, Insomnia Severity Index; PCS, Pain Catastrophizing Scale; PHQ-9, Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index.